52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Sicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.Peer-Reviewed Original ResearchCharacterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
Silverberg J, Cronin A, Jones E, Dave S, McLean R, Greenberg J, Strober B, Bieber T, Gooderham M, Paller A, Simpson E. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. JAAD International 2024, 15: 127-130. PMID: 38545488, PMCID: PMC10966280, DOI: 10.1016/j.jdin.2023.11.015.Peer-Reviewed Original Research